Understanding how a specific protein degradation process affects heart growth
Non-canonical ERAD as a Regulator of Cardiac Hypertrophy
This study is looking at how a special system in the heart helps manage a protein that can promote heart growth when the heart is under stress, which could lead to better treatments for people with heart conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11010373 on NIH RePORTER |
What this research studies
This research investigates a unique role of a protein degradation system in the heart, particularly how it regulates a growth-promoting protein called SGK1 during conditions of increased heart stress. The study focuses on the endoplasmic reticulum's ability to manage misfolded proteins and how this process can influence heart muscle growth in response to pressure overload. By examining the interactions between SGK1 and its protective binding partner, GILZ, the research aims to uncover new insights into cardiac hypertrophy, a condition where the heart muscle thickens and can lead to heart failure. Patients may benefit from understanding how these mechanisms work, potentially leading to new treatments for heart diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that lead to cardiac hypertrophy, such as hypertension or heart valve disease.
Not a fit: Patients with non-cardiac related conditions or those without any form of cardiac hypertrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating cardiac hypertrophy and related heart conditions.
How similar studies have performed: While the specific approach of investigating non-canonical ERAD in cardiac hypertrophy is novel, related research has shown success in understanding protein degradation mechanisms in other contexts.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Glembotski, Chris — University of Arizona
- Study coordinator: Glembotski, Chris
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.